Related Experiment Video
Updated: Nov 3, 2025
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Major clinical research advances in gynecologic cancer in 2020
Yoo Young Lee1, Min Chul Choi2, Jeong Yeol Park3
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract:
In 2020 series, we summarized the major clinical research advances in gynecologic oncology with providing representative figures of the most influential study for 1 of each 3 gynecologic cancers: cervix, ovary, and uterine corpus. Review for cervical cancer covered targeted agents and immune checkpoint inhibitors, adjuvant radiation therapy or concurrent/sequential chemoradiation therapy after radical hysterectomy in early cervical cancer, radical surgery in early cervical cancer; and prevention and screening. Ovarian cancer research included studies of various combinations of poly (ADP-ribose) polymerase inhibitors with chemotherapy, immune checkpoint inhibitors, and/or vascular endothelial growth factor inhibitors according to the clinical setting. For uterine corpus cancer, molecular classification upon which the decision of adjuvant treatments might be based, World Health Organization recommendation of 2-tier grading system (low grade vs. high grade), sentinel lymph node assessment and ovarian preservation in clinically early-stage endometrial cancer were reviewed. Molecular targeted agents including immune checkpoint inhibitors which showed promising anti-tumor activities in advanced/recurrent endometrial cancer were also included in this review.
Insights
This review highlights key 2020 clinical research in gynecologic oncology, focusing on cervical, ovarian, and uterine corpus cancers. Advances include targeted therapies, immunotherapy, and refined treatment strategies for better patient outcomes.
Area of Science:
- Gynecologic Oncology
- Clinical Cancer Research
- Oncologic Therapeutics
Background:
- The 2020 series provides a comprehensive overview of significant clinical research advancements.
- Focuses on three major gynecologic cancers: cervix, ovary, and uterine corpus.
- Highlights influential studies and their impact on treatment paradigms.
Purpose of the Study:
- To summarize major clinical research advances in gynecologic oncology from 2020.
- To present representative studies for cervical, ovarian, and uterine corpus cancers.
- To inform clinicians about the latest evidence-based treatment strategies.
Main Methods:
- Review of major clinical research published in 2020.
- Inclusion of influential studies for cervical, ovarian, and uterine corpus cancers.
- Categorization of research by cancer type and treatment modality.
Main Results:
- Cervical cancer: advances in targeted agents, immunotherapy, adjuvant radiation, and surgical approaches.
- Ovarian cancer: novel combinations of PARP inhibitors, chemotherapy, immunotherapy, and VEGF inhibitors.
- Uterine corpus cancer: molecular classification, grading systems, sentinel lymph node assessment, ovarian preservation, and targeted agents for advanced/recurrent disease.
Conclusions:
- Significant progress in targeted therapies and immunotherapies across gynecologic cancers.
- Refined understanding of molecular drivers and personalized treatment approaches.
- Emphasis on evidence-based strategies for improved patient management and outcomes.
More Related Videos
07:50Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
Published on: April 18, 2025
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:11Clinical Trials: Overview